Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...

In the world of biomedical innovation, few stories embody the spirit of perseverance, intuition, and collaboration quite like ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 12.4% year on year to ...

The group says its vaccine business will recover in the medium term when falling immunisation rates cause a severe public ...

Q1 2026 Earnings Call November 5, 2025 9:00 AM ESTCompany ParticipantsDavid Clair - VP of Investor Relations & ...

At a time when volatility strikes every second day, investors often rely on value investing rather than other options like growth or momentum. As soon as other investors start selling their stocks at ...

Hosts David and Gina explore the unexpected origins of blockbuster diabetes and weight-loss drugs like Ozempic and Wegovy ...

A new Brain Medicine review maps how gut microbes influence sleep disorders, from insomnia and sleep apnea to circadian ...

Novo Nordisk A/S delivered mixed Q3 '25 results, with modest revenue growth but 27% drop in net profit due to financing costs ...

The number of customer satisfaction (CSAT) responses for Zifo's LCS service has doubled since 2021, reflecting increased ...